IBDEI2L6 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,43901,1,4,0)
 ;;=4^N94.810
 ;;^UTILITY(U,$J,358.3,43901,2)
 ;;=^336618
 ;;^UTILITY(U,$J,358.3,43902,0)
 ;;=N94.818^^170^2107^101
 ;;^UTILITY(U,$J,358.3,43902,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43902,1,3,0)
 ;;=3^Vulvodynia,Other
 ;;^UTILITY(U,$J,358.3,43902,1,4,0)
 ;;=4^N94.818
 ;;^UTILITY(U,$J,358.3,43902,2)
 ;;=^5015923
 ;;^UTILITY(U,$J,358.3,43903,0)
 ;;=N94.819^^170^2107^102
 ;;^UTILITY(U,$J,358.3,43903,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43903,1,3,0)
 ;;=3^Vulvodynia,Unspec
 ;;^UTILITY(U,$J,358.3,43903,1,4,0)
 ;;=4^N94.819
 ;;^UTILITY(U,$J,358.3,43903,2)
 ;;=^5015924
 ;;^UTILITY(U,$J,358.3,43904,0)
 ;;=I05.8^^170^2108^17
 ;;^UTILITY(U,$J,358.3,43904,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43904,1,3,0)
 ;;=3^Rheumatic Mitral Valve Disease NEC
 ;;^UTILITY(U,$J,358.3,43904,1,4,0)
 ;;=4^I05.8
 ;;^UTILITY(U,$J,358.3,43904,2)
 ;;=^5007043
 ;;^UTILITY(U,$J,358.3,43905,0)
 ;;=I10.^^170^2108^9
 ;;^UTILITY(U,$J,358.3,43905,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43905,1,3,0)
 ;;=3^Hypertension,Essential
 ;;^UTILITY(U,$J,358.3,43905,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,43905,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,43906,0)
 ;;=I25.2^^170^2108^15
 ;;^UTILITY(U,$J,358.3,43906,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43906,1,3,0)
 ;;=3^Old MI
 ;;^UTILITY(U,$J,358.3,43906,1,4,0)
 ;;=4^I25.2
 ;;^UTILITY(U,$J,358.3,43906,2)
 ;;=^259884
 ;;^UTILITY(U,$J,358.3,43907,0)
 ;;=I25.10^^170^2108^4
 ;;^UTILITY(U,$J,358.3,43907,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43907,1,3,0)
 ;;=3^Athscl Hrt Disease,Native Coronary Artery, w/o Ang Pctrs
 ;;^UTILITY(U,$J,358.3,43907,1,4,0)
 ;;=4^I25.10
 ;;^UTILITY(U,$J,358.3,43907,2)
 ;;=^5007107
 ;;^UTILITY(U,$J,358.3,43908,0)
 ;;=I25.810^^170^2108^1
 ;;^UTILITY(U,$J,358.3,43908,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43908,1,3,0)
 ;;=3^Atherosclerosis of CABG w/o Angina Pectoris
 ;;^UTILITY(U,$J,358.3,43908,1,4,0)
 ;;=4^I25.810
 ;;^UTILITY(U,$J,358.3,43908,2)
 ;;=^5007141
 ;;^UTILITY(U,$J,358.3,43909,0)
 ;;=I25.811^^170^2108^3
 ;;^UTILITY(U,$J,358.3,43909,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43909,1,3,0)
 ;;=3^Athscl Hrt Disease of Transplanted Hrt w/o Ang Pctrs
 ;;^UTILITY(U,$J,358.3,43909,1,4,0)
 ;;=4^I25.811
 ;;^UTILITY(U,$J,358.3,43909,2)
 ;;=^5007142
 ;;^UTILITY(U,$J,358.3,43910,0)
 ;;=I25.812^^170^2108^2
 ;;^UTILITY(U,$J,358.3,43910,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43910,1,3,0)
 ;;=3^Athscl Bypass Cor Art of Transplanted Hrt w/o Ang Pctrs
 ;;^UTILITY(U,$J,358.3,43910,1,4,0)
 ;;=4^I25.812
 ;;^UTILITY(U,$J,358.3,43910,2)
 ;;=^5007143
 ;;^UTILITY(U,$J,358.3,43911,0)
 ;;=I35.0^^170^2108^10
 ;;^UTILITY(U,$J,358.3,43911,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43911,1,3,0)
 ;;=3^Nonrhematic Aortic Valve Stenosis
 ;;^UTILITY(U,$J,358.3,43911,1,4,0)
 ;;=4^I35.0
 ;;^UTILITY(U,$J,358.3,43911,2)
 ;;=^5007174
 ;;^UTILITY(U,$J,358.3,43912,0)
 ;;=I35.1^^170^2108^13
 ;;^UTILITY(U,$J,358.3,43912,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43912,1,3,0)
 ;;=3^Nonrheumatic Aortic Valve Insufficiency
 ;;^UTILITY(U,$J,358.3,43912,1,4,0)
 ;;=4^I35.1
 ;;^UTILITY(U,$J,358.3,43912,2)
 ;;=^5007175
 ;;^UTILITY(U,$J,358.3,43913,0)
 ;;=I35.2^^170^2108^14
 ;;^UTILITY(U,$J,358.3,43913,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43913,1,3,0)
 ;;=3^Nonrheumatic Aortic Valve Stenosis w/ Insufficiency
 ;;^UTILITY(U,$J,358.3,43913,1,4,0)
 ;;=4^I35.2
 ;;^UTILITY(U,$J,358.3,43913,2)
 ;;=^5007176
 ;;^UTILITY(U,$J,358.3,43914,0)
 ;;=I35.8^^170^2108^11
 ;;^UTILITY(U,$J,358.3,43914,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43914,1,3,0)
 ;;=3^Nonrheumatic Aortic Valve Disorders NEC
